JP Morgan Maintains Momenta Pharmaceuticals to Overweight with Price Target $15.00

Brokerage firm JP Morgan Maintains its rating on Momenta Pharmaceuticals(NASDAQ:MNTA). In a research note issued to the investors, the brokerage major Lowers the price-target to $15.00 per share. The shares have been rated Overweight. The rating by JP Morgan was issued on Aug 5, 2016.

In a different note, Goldman Sachs said it Initiates Coverage on Momenta Pharmaceuticals, according to a research note issued on Jun 6, 2016. The shares have been rated ‘Neutral’ by the firm.

Momenta Pharmaceuticals (MNTA) made into the market gainers list on Wednesdays trading session with the shares advancing 1.19% or 0.14 points. Due to strong positive momentum, the stock ended at $11.93, which is also near the day’s high of $12.105. The stock began the session at $11.79 and the volume stood at 2,79,167 shares. The 52-week high of the shares is $22.82 and the 52 week low is $7.86. The company has a current market capitalization of $844 M and it has 7,07,44,044 shares in outstanding.

Momenta Pharmaceuticals(MNTA) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $26.43M. Analysts had an estimated revenue of $23.55M. Earnings per share were $-0.31. Analysts had estimated an EPS of $-0.32.

Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, Bennett M Shapiro (director) sold 5,200 shares at $13.00 per share price.Also, On May 23, 2016, Craig A Wheeler (President) sold 5,880 shares at $10.18 per share price.On May 23, 2016, Bruce Leicher (SVP & General Counsel) sold 1,000 shares at $10.40 per share price, according to the Form-4 filing with the securities and exchange commission.

Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Company’s product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *